PharmaMar suffers late-stage failure for RNAi-based therapy in dry-eye disease
09 Feb 2024
Phase 3OligonucleotidesiRNA
PharmaMar said Friday that a Phase III study of the RNAi-based therapy tivanisiran for the treatment of dry-eye disease associated with Sjögren’s Syndrome failed to meet its primary endpoint. Tivanisiran is being developed by the company’s Sylentis subsidiary and is its lead programme
The study randomised 203 patients dry-eye associated with Sjögren’s Syndrome to receive tivanisiran eye drops or vehicle once daily for 3 months. According to an entry on ClinicalTrials.gov, the main goals measured change from baseline in corneal fluorescein staining (CFS) scale and change from baseline in dry eye symptom scale.
Tivanisiran, also known as SYL1001, is a small synthetic double-stranded RNA oligonucleotide designed to selectively inhibit production of the transient receptor potential cation channel TRPV1.
More to come.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.